Which has preferable valuation and earnings, EMBC or LUNG?

Embecta has higher revenue and earnings than Pulmonx. Pulmonx is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Embecta $1.08B 0.20 $95.40M $1.90 1.96 Pulmonx $90.50M 0.99 -$54M -$1.16 N/A

Is EMBC or LUNG more profitable?

Embecta has a net margin of 10.73% compared to Pulmonx's net margin of -55.03%. Embecta's return on equity of -23.96% beat Pulmonx's return on equity. Company Net Margins Return on Equity Return on Assets Embecta 10.73% -23.96% 14.12% Pulmonx -55.03% -90.27% -37.25%

Does the media prefer EMBC or LUNG?

In the previous week, Embecta had 28 more articles in the media than Pulmonx. MarketBeat recorded 39 mentions for Embecta and 11 mentions for Pulmonx. Pulmonx's average media sentiment score of 0.33 beat Embecta's score of 0.04 indicating that Pulmonx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Embecta 1 Very Positive mention(s) 1 Positive mention(s) 37 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pulmonx 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Is LUCD or LUNG more profitable?

Pulmonx has a net margin of -55.03% compared to Lucid Diagnostics' net margin of -876.72%. Lucid Diagnostics' return on equity of 0.00% beat Pulmonx's return on equity. Company Net Margins Return on Equity Return on Assets Lucid Diagnostics -876.72% N/A -116.26% Pulmonx -55.03% -90.27% -37.25%

Does the media favor LUCD or LUNG?

In the previous week, Pulmonx had 9 more articles in the media than Lucid Diagnostics. MarketBeat recorded 11 mentions for Pulmonx and 2 mentions for Lucid Diagnostics. Lucid Diagnostics' average media sentiment score of 0.45 beat Pulmonx's score of 0.33 indicating that Lucid Diagnostics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lucid Diagnostics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pulmonx 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has better earnings & valuation, INFU or LUNG?

InfuSystem has higher revenue and earnings than Pulmonx. Pulmonx is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InfuSystem $142.40M 1.31 $870K $0.38 24.26 Pulmonx $90.50M 0.99 -$54M -$1.16 N/A

Is INFU or LUNG more profitable?

InfuSystem has a net margin of 1.12% compared to Pulmonx's net margin of -55.03%. InfuSystem's return on equity of 2.78% beat Pulmonx's return on equity. Company Net Margins Return on Equity Return on Assets InfuSystem 1.12% 2.78% 1.41% Pulmonx -55.03% -90.27% -37.25%

Does the media prefer INFU or LUNG?

In the previous week, Pulmonx had 10 more articles in the media than InfuSystem. MarketBeat recorded 11 mentions for Pulmonx and 1 mentions for InfuSystem. Pulmonx's average media sentiment score of 0.33 beat InfuSystem's score of 0.00 indicating that Pulmonx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InfuSystem 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pulmonx 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer KRMD or LUNG?

In the previous week, Pulmonx had 8 more articles in the media than KORU Medical Systems. MarketBeat recorded 11 mentions for Pulmonx and 3 mentions for KORU Medical Systems. KORU Medical Systems' average media sentiment score of 0.65 beat Pulmonx's score of 0.33 indicating that KORU Medical Systems is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment KORU Medical Systems 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pulmonx 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has higher earnings and valuation, LUNG or PDEX?

Pro-Dex has lower revenue, but higher earnings than Pulmonx. Pulmonx is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pulmonx $90.50M 0.99 -$54M -$1.16 N/A Pro-Dex $66.59M 3.05 $8.98M $3.62 17.57

Is LUNG or PDEX more profitable?

Pro-Dex has a net margin of 16.08% compared to Pulmonx's net margin of -55.03%. Pro-Dex's return on equity of 22.78% beat Pulmonx's return on equity. Company Net Margins Return on Equity Return on Assets Pulmonx -55.03% -90.27% -37.25% Pro-Dex 16.08% 22.78% 14.30%

Pulmonx (LUNG) Competitors

$2.12 +0.49 (+30.06%)

Closing price 08/3/2026 04:00 PM Eastern

Extended Trading

$2.11 -0.01 (-0.52%)

As of 08/3/2026 07:57 PM Eastern

Compare

LUNG vs. EMBC, LUCD, INFU, KRMD, and PDEX

Should you buy Pulmonx stock or one of its competitors? MarketBeat compares Pulmonx with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Pulmonx include Embecta (EMBC), Lucid Diagnostics (LUCD), InfuSystem (INFU), KORU Medical Systems (KRMD), and Pro-Dex (PDEX).

How does Pulmonx compare to Embecta?

Embecta (NASDAQ:EMBC) and Pulmonx (NASDAQ:LUNG) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation, profitability and media sentiment.

Embecta currently has a consensus price target of $11.00, indicating a potential upside of 195.70%. Pulmonx has a consensus price target of $7.67, indicating a potential upside of 261.64%. Given Pulmonx's stronger consensus rating and higher possible upside, analysts clearly believe Pulmonx is more favorable than Embecta.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Embecta	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60
Pulmonx	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Embecta has a beta of 0.81, meaning that its share price is 19% less volatile than the broader market. Comparatively, Pulmonx has a beta of 0.28, meaning that its share price is 72% less volatile than the broader market.

Embecta has a net margin of 10.73% compared to Pulmonx's net margin of -55.03%. Embecta's return on equity of -23.96% beat Pulmonx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Embecta	10.73%	-23.96%	14.12%
Pulmonx	-55.03%	-90.27%	-37.25%

In the previous week, Embecta had 28 more articles in the media than Pulmonx. MarketBeat recorded 39 mentions for Embecta and 11 mentions for Pulmonx. Pulmonx's average media sentiment score of 0.33 beat Embecta's score of 0.04 indicating that Pulmonx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Embecta	1 Very Positive mention(s)	1 Positive mention(s)	37 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pulmonx	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Embecta has higher revenue and earnings than Pulmonx. Pulmonx is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Embecta	$1.08B	0.20	$95.40M	$1.90	1.96
Pulmonx	$90.50M	0.99	-$54M	-$1.16	N/A

93.8% of Embecta shares are owned by institutional investors. Comparatively, 91.0% of Pulmonx shares are owned by institutional investors. 1.3% of Embecta shares are owned by insiders. Comparatively, 7.5% of Pulmonx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Embecta beats Pulmonx on 10 of the 16 factors compared between the two stocks.

How does Pulmonx compare to Lucid Diagnostics?

Lucid Diagnostics (NASDAQ:LUCD) and Pulmonx (NASDAQ:LUNG) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends, media sentiment and valuation.

In the previous week, Pulmonx had 9 more articles in the media than Lucid Diagnostics. MarketBeat recorded 11 mentions for Pulmonx and 2 mentions for Lucid Diagnostics. Lucid Diagnostics' average media sentiment score of 0.45 beat Pulmonx's score of 0.33 indicating that Lucid Diagnostics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lucid Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pulmonx	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Pulmonx has a net margin of -55.03% compared to Lucid Diagnostics' net margin of -876.72%. Lucid Diagnostics' return on equity of 0.00% beat Pulmonx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lucid Diagnostics	-876.72%	N/A	-116.26%
Pulmonx	-55.03%	-90.27%	-37.25%

74.0% of Lucid Diagnostics shares are owned by institutional investors. Comparatively, 91.0% of Pulmonx shares are owned by institutional investors. 6.9% of Lucid Diagnostics shares are owned by insiders. Comparatively, 7.5% of Pulmonx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Pulmonx has higher revenue and earnings than Lucid Diagnostics. Lucid Diagnostics is trading at a lower price-to-earnings ratio than Pulmonx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lucid Diagnostics	$4.71M	41.75	-$58.01M	-$0.47	N/A
Pulmonx	$90.50M	0.99	-$54M	-$1.16	N/A

Lucid Diagnostics has a beta of 1.08, meaning that its stock price is 8% more volatile than the broader market. Comparatively, Pulmonx has a beta of 0.28, meaning that its stock price is 72% less volatile than the broader market.

Lucid Diagnostics presently has a consensus price target of $4.19, suggesting a potential upside of 332.41%. Pulmonx has a consensus price target of $7.67, suggesting a potential upside of 261.64%. Given Lucid Diagnostics' stronger consensus rating and higher possible upside, research analysts plainly believe Lucid Diagnostics is more favorable than Pulmonx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lucid Diagnostics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Pulmonx	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Lucid Diagnostics and Pulmonx tied by winning 8 of the 16 factors compared between the two stocks.

How does Pulmonx compare to InfuSystem?

InfuSystem (NYSE:INFU) and Pulmonx (NASDAQ:LUNG) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability, media sentiment and valuation.

71.1% of InfuSystem shares are owned by institutional investors. Comparatively, 91.0% of Pulmonx shares are owned by institutional investors. 10.8% of InfuSystem shares are owned by company insiders. Comparatively, 7.5% of Pulmonx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Pulmonx had 10 more articles in the media than InfuSystem. MarketBeat recorded 11 mentions for Pulmonx and 1 mentions for InfuSystem. Pulmonx's average media sentiment score of 0.33 beat InfuSystem's score of 0.00 indicating that Pulmonx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InfuSystem	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pulmonx	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

InfuSystem has a net margin of 1.12% compared to Pulmonx's net margin of -55.03%. InfuSystem's return on equity of 2.78% beat Pulmonx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InfuSystem	1.12%	2.78%	1.41%
Pulmonx	-55.03%	-90.27%	-37.25%

InfuSystem presently has a consensus target price of $15.00, indicating a potential upside of 62.69%. Pulmonx has a consensus target price of $7.67, indicating a potential upside of 261.64%. Given Pulmonx's higher possible upside, analysts clearly believe Pulmonx is more favorable than InfuSystem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InfuSystem	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Pulmonx	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

InfuSystem has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market. Comparatively, Pulmonx has a beta of 0.28, indicating that its share price is 72% less volatile than the broader market.

InfuSystem has higher revenue and earnings than Pulmonx. Pulmonx is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InfuSystem	$142.40M	1.31	$870K	$0.38	24.26
Pulmonx	$90.50M	0.99	-$54M	-$1.16	N/A

Summary

InfuSystem beats Pulmonx on 11 of the 16 factors compared between the two stocks.

How does Pulmonx compare to KORU Medical Systems?

KORU Medical Systems (NASDAQ:KRMD) and Pulmonx (NASDAQ:LUNG) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.

58.6% of KORU Medical Systems shares are held by institutional investors. Comparatively, 91.0% of Pulmonx shares are held by institutional investors. 18.5% of KORU Medical Systems shares are held by insiders. Comparatively, 7.5% of Pulmonx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

KORU Medical Systems has higher earnings, but lower revenue than Pulmonx. KORU Medical Systems is trading at a lower price-to-earnings ratio than Pulmonx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KORU Medical Systems	$41.13M	4.72	-$2.64M	-$0.05	N/A
Pulmonx	$90.50M	0.99	-$54M	-$1.16	N/A

KORU Medical Systems currently has a consensus price target of $7.25, indicating a potential upside of 71.39%. Pulmonx has a consensus price target of $7.67, indicating a potential upside of 261.64%. Given Pulmonx's higher possible upside, analysts clearly believe Pulmonx is more favorable than KORU Medical Systems.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KORU Medical Systems	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Pulmonx	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Pulmonx had 8 more articles in the media than KORU Medical Systems. MarketBeat recorded 11 mentions for Pulmonx and 3 mentions for KORU Medical Systems. KORU Medical Systems' average media sentiment score of 0.65 beat Pulmonx's score of 0.33 indicating that KORU Medical Systems is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
KORU Medical Systems	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pulmonx	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

KORU Medical Systems has a net margin of -5.27% compared to Pulmonx's net margin of -55.03%. KORU Medical Systems' return on equity of -13.61% beat Pulmonx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
KORU Medical Systems	-5.27%	-13.61%	-8.33%
Pulmonx	-55.03%	-90.27%	-37.25%

KORU Medical Systems has a beta of 0.45, suggesting that its share price is 55% less volatile than the broader market. Comparatively, Pulmonx has a beta of 0.28, suggesting that its share price is 72% less volatile than the broader market.

Summary

KORU Medical Systems beats Pulmonx on 11 of the 16 factors compared between the two stocks.

How does Pulmonx compare to Pro-Dex?

Pulmonx (NASDAQ:LUNG) and Pro-Dex (NASDAQ:PDEX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, institutional ownership, earnings, analyst recommendations, valuation and risk.

Pro-Dex has a net margin of 16.08% compared to Pulmonx's net margin of -55.03%. Pro-Dex's return on equity of 22.78% beat Pulmonx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulmonx	-55.03%	-90.27%	-37.25%
Pro-Dex	16.08%	22.78%	14.30%

Pulmonx has a beta of 0.28, meaning that its stock price is 72% less volatile than the broader market. Comparatively, Pro-Dex has a beta of 0.02, meaning that its stock price is 98% less volatile than the broader market.

Pulmonx currently has a consensus target price of $7.67, indicating a potential upside of 261.64%. Pro-Dex has a consensus target price of $70.00, indicating a potential upside of 10.05%. Given Pulmonx's stronger consensus rating and higher probable upside, research analysts clearly believe Pulmonx is more favorable than Pro-Dex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulmonx	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Pro-Dex	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33

Pro-Dex has lower revenue, but higher earnings than Pulmonx. Pulmonx is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulmonx	$90.50M	0.99	-$54M	-$1.16	N/A
Pro-Dex	$66.59M	3.05	$8.98M	$3.62	17.57

91.0% of Pulmonx shares are owned by institutional investors. Comparatively, 15.3% of Pro-Dex shares are owned by institutional investors. 7.5% of Pulmonx shares are owned by company insiders. Comparatively, 45.9% of Pro-Dex shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Pulmonx had 11 more articles in the media than Pro-Dex. MarketBeat recorded 11 mentions for Pulmonx and 0 mentions for Pro-Dex. Pulmonx's average media sentiment score of 0.33 beat Pro-Dex's score of 0.00 indicating that Pulmonx is being referred to more favorably in the media.

Company	Overall Sentiment
Pulmonx	Neutral
Pro-Dex	Neutral

Summary

Pulmonx and Pro-Dex tied by winning 8 of the 16 factors compared between the two stocks.

Get Pulmonx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LUNG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LUNG vs. The Competition

Export

Metric	Pulmonx	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$68.85M	$5.67B	$6.86B	$12.44B
Dividend Yield	N/A	1.78%	2.60%	10.03%
P/E Ratio	-1.83	23.62	280.72	24.99
Price / Sales	0.99	58.66	588.10	90.57
Price / Cash	N/A	32.53	28.64	34.82
Price / Book	1.62	6.50	11.02	6.21
Net Income	-$54M	$151.15M	$3.48B	$347.49M
7 Day Performance	69.60%	3.01%	0.80%	1.29%
1 Month Performance	52.52%	-1.18%	-4.17%	-3.59%
1 Year Performance	28.48%	3.40%	61.47%	18.38%

Pulmonx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LUNG Pulmonx	2.9574 of 5 stars	$2.12 +30.1%	$7.67 +261.6%	+31.7%	$68.85M	$90.50M	N/A	250	Earnings Report Gap Up High Trading Volume
EMBC Embecta	4.2718 of 5 stars	$3.43 +4.3%	$11.00 +220.7%	-62.7%	$195.19M	$1.08B	1.81	1,850	Trending News Upcoming Earnings
LUCD Lucid Diagnostics	3.5073 of 5 stars	$0.90 -0.5%	$4.19 +363.5%	-3.2%	$184.30M	$4.71M	N/A	70	Gap Up
INFU InfuSystem	4.0435 of 5 stars	$9.36 +2.6%	$15.00 +60.3%	+61.8%	$184.06M	$142.40M	156.03	410
KRMD KORU Medical Systems	3.4451 of 5 stars	$4.08 +6.5%	$7.25 +77.7%	+21.6%	$175.92M	$43.26M	N/A	80	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LUNG) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pulmonx (LUNG) Competitors